Eliglustat is a first-line oral treatment for adults with Gaucher disease type 1 who have an extensive, intermediate or poor CYP2D6 metabolizer phenotype (> 90% of patients). The gene discussed is CYP2D6; the disease is Gaucher disease type 1.